Patent ID: 7718357

Claim:
A method of inhibiting disease caused by a dengue virus infection, the method comprising: a) in a first administration, administering to a subject an effective amount of a first and second vaccinal dengue virus serotype; and b) in a second administration, administering to the subject an effective amount of a third and fourth vaccinal dengue virus serotype wherein i) the first, second, third, and fourth vaccinal dengue virus serotypes are each different one from another; ii) the second administration occurs from about 30 days to about 1 year after the first administration; iii) each vaccinal dengue virus serotypes is administered in an amount that is sufficient to induce a homologous immune response; iv) the first and second serotypes are administered in separate dosages forms or together in a single dosage form; v) the third and fourth serotypes are administered in separate dosages forms or together in a single dosage form; and vi) each of the dengue virus serotypes is a live, attenuated virus.